Elevance Health
ELV
1,523 hedge funds and large institutions have $93B invested in Elevance Health in 2023 Q2 according to their latest regulatory filings, with 115 funds opening new positions, 580 increasing their positions, 584 reducing their positions, and 99 closing their positions.
42% more call options, than puts
Call options by funds: $682M | Put options by funds: $479M
16% more first-time investments, than exits
New positions opened: 115 | Existing positions closed: 99
0% more funds holding
Funds holding: 1,516 → 1,523 (+7)
1% less repeat investments, than reductions
Existing positions increased: 580 | Existing positions reduced: 584
4% less capital invested
Capital invested by funds: $96.9B → $93B (-$3.87B)
1.2% less ownership
Funds ownership: 89.78% → 88.58% (-1.2%)
8% less funds holding in top 10
Funds holding in top 10: 49 → 45 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Veritas Asset Management
London,
United Kingdom
|
+$523M |
| 2 |
JP Morgan Chase
New York
|
+$255M |
| 3 |
Man Group
London,
United Kingdom
|
+$237M |
| 4 |
Barclays
London,
United Kingdom
|
+$202M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$190M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$1.21B |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$618M |
| 3 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$594M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$542M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$522M |
ELV Hedge Fund Activity: Q2 2023 in Review
1,523 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Elevance Health (ELV) for Q2 2023, worth a combined $93B — down 4% from $96.9B a quarter earlier.
Buyers outnumbered sellers: 115 funds opened new ELV positions and 99 closed out — a net gain of 16 holders — while 580 added to existing stakes and 584 trimmed.
The largest buyer was Veritas Asset Management, opening a new position worth an estimated $523M. The largest seller was Envestnet Asset Management, cutting an estimated $1.21B.
- 1,523 institutional investors held Elevance Health (ELV) as of Q2 2023, up from 1,516 in Q1 2023.
- Funds reported $93B of Elevance Health stock for Q2 2023, down 4% quarter-over-quarter.
- 115 funds opened new Elevance Health positions in Q2 2023 and 99 closed out, a net change of +16 holders.
- The largest Elevance Health buyer in Q2 2023 was Veritas Asset Management, an estimated $523M added.
- The largest Elevance Health seller in Q2 2023 was Envestnet Asset Management, an estimated $1.21B sold.
Based on aggregated 13F filings for Q2 2023.